非霍奇金淋巴瘤

预约门诊

分期

如果确诊非霍奇金淋巴瘤，下一步是确定这种癌症的严重程度（分期）。影像学检查、血液检测和活检可用于确定非霍奇金淋巴瘤的分期。医疗护理团队会使用癌症分期来帮助制定治疗计划。

非霍奇金淋巴瘤的分期范围为 1 期至 4 期：

  • 1 期非霍奇金淋巴瘤。 在此分期，仅单个淋巴结区域或单个淋巴结外部位受累。
  • 2 期非霍奇金淋巴瘤。 2 期是指横膈膜同侧的两个或两个以上淋巴结区域受累。
  • 3 期非霍奇金淋巴瘤。 3 期是指横膈膜两侧的淋巴结区域受累，或横膈膜上方的淋巴结及脾脏均受累。
  • 4 期非霍奇金淋巴瘤。 4 期是指非霍奇金淋巴瘤已扩散至淋巴系统以外的器官。

非霍奇金淋巴瘤预后

癌症预后反映癌症可被治疗或治愈的可能性。预后可能取决于以下因素：

  • 您的年龄。
  • 您的整体健康状况。
  • 您所患的非霍奇金淋巴瘤类型。
  • 癌症分期。
  • 您的血液检测结果。

如果您想了解治疗后的情况，请与医疗护理团队讨论您的预后。医疗护理团队的成员可以解释在评估您的预后时会考虑哪些因素。

申请预约
诊断与治疗生存率
Nov. 07, 2025

Living with 非霍奇金淋巴瘤?

Connect with others like you for support and answers to your questions in the Blood Cancers & Disorders support group on Mayo Clinic Connect, a patient community.

Blood Cancers & Disorders Discussions

Anonymous
Has anyone been diagnosed with POEMS syndrome?

30 Replies Sun, Jun 07, 2026

hikerny
Anyone have chronic lymphocytic leukemia (CLL)?

333 Replies Sun, Jun 07, 2026

See more discussions
  1. B-cell lymphomas. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480. Accessed Aug. 30, 2024.
  2. T-cell lymphomas. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1483. Accessed Aug. 30, 2024.
  3. Non-Hodgkin lymphoma (NHL). Leukemia & Lymphoma Society. https://www.lls.org/lymphoma/non-hodgkin-lymphoma. Accessed Sept. 16, 2024.
  4. DeVita VT Jr, et al., eds. Non-Hodgkin lymphoma. In: DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 12th ed. Wolters Kluwer; 2023. Accessed Aug. 28, 2024.
  5. Distress management. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1431. Accessed Aug. 29, 2024.
  6. Member institutions. Alliance for Clinical Trials in Oncology. https://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=%2FPublic%2FInstitutions. Accessed Sept. 17, 2024.
  7. Member institution lists. NRG Oncology. https://www.nrgoncology.org/About-Us/Membership/Member-Institution-Lists. Accessed Sept. 17, 2024.
  8. Bock AM, et al. Bispecific antibodies for non-Hodgkin lymphoma treatment. Current Treatment Options in Oncology. 2022; doi:10.1007/s11864-021-00925-1.
  9. Tun AM, et al. Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies. Cancer Treatment Reviews. 2020; doi:10.1016/j.ctrv.2020.102042.
  10. Nowakowski GS, et al. Integrating precision medicine through evaluation of cell of origin treatment planning for diffuse large B-cell lymphoma. Blood Cancer Journal. 2019; doi:10.1038/s41408-019-0208-6.
  11. Laurent C, et al. Impact of expert pathologic review of lymphoma diagnosis: Study of patients from the French Lymphopath Network. Journal of Clinical Oncology. 2017; doi:10.1200/JCO.2016.71.2083.
  12. Paulson CL. Allscripts EPSi. Mayo Clinic. July 15, 2025.
  13. Cancer stat facts: Non-Hodgkin lymphoma. National Cancer Institute. https://seer.cancer.gov/statfacts/html/nhl.html. Accessed Oct. 1, 2025.
  14. Non-Hodgkin lymphoma treatment (PDQ) — Patient version. National Cancer Institute. https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq. Accessed Oct. 1, 2025.
  15. Elsevier Point of Care. Clinical Overview: Non-Hodgkin lymphoma. https://www.clinicalkey.com. Accessed Oct. 1, 2025.
  16. Cancer stat facts: NHL — Diffuse large B-cell lymphoma (DLBCL). National Cancer Institute. https://seer.cancer.gov/statfacts/html/dlbcl.html. Accessed Oct. 1, 2025.
  17. Cancer stat facts: NHL — Follicular lymphoma. National Cancer Institute. https://seer.cancer.gov/statfacts/html/follicular.html. Accessed Oct. 1, 2025.

相关

相关医疗程序

Mayo Clinic 新闻

产品与服务

非霍奇金淋巴瘤